Literature DB >> 227930

Lipolysis produces changes in the immunoreactivity and cell reactivity of very low density lipoproteins.

G Schonfeld, W Patsch, B Pfleger, J L Witztum, S W Weidman.   

Abstract

Smaller very low density lipoprotein (VLDL) remnants interact more readily with tissues than do larger "intact" VLDL. This may be related to changes in the availability of VLDL apoproteins on the surface of the lipoproteins. To test this hypothesis VLDL were incubated at 37 degrees C with bovine milk lipase (LPL), and the abilities of LPL-treated VLDL preparations to compete with (125)I-low density lipoproteins (LDL) for interaction with cultured normal human fibroblasts were measured. At the same time, the immunologic activities of these preparations were also tested by double antibody radioimmunoassay. Triglyceride (TG) contents of VLDL fell by 30-90% during incubation with LPL and, on zonal ultracentrifugation, VLDL of faster Svedberg unit of flotation (S(f1.063)) rates (>150) were gradually converted to smaller VLDL with lower S(f) rates (21-60). LPL-treated VLDL competed two to five times more effectively with (125)I-LDL for binding to cellular receptors than did control VLDL. Control VLDL incubated with heat-inactivated LPL at 37 degrees C, or with active LPL at 4 degrees C had unaltered cell reactivities and TG contents compared with VLDL incubated without any enzyme. The direct uptake and degradation of LPL-treated VLDL was also assessed by using VLDL (125)I-labeled in apoprotein (Apo)B. LPL-treated VLDL-(125)I-ApoB were taken up and degraded by fibroblast at greater rates than were control VLDL-(125)I-ApoB. Thus, hydrolysis of VLDL lipids was accompanied by an increased ability of VLDL to interact with fibroblasts. The immunoreactivity of ApoB in the same VLDL preparations, expressed as the "apparent ApoB contents" of LPL-treated VLDL, increased by 10-50% (P < 0.02) in those assays that contained anti-LDL antisera, but the ApoB of control VLDL remained constant. However, assays that contained antisera directed against ApoB isolated from VLDL did not distinguish between LPL-treated and control VLDL. Thus, VLDL lipid hydrolysis was accompanied by changes in the immunoreactivity of VLDL-ApoB, which probably reflect changes in the disposition of ApoB on the surface of VLDL. The altered disposition of ApoB on VLDL "remnants" may be related to their enhanced interaction with cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 227930      PMCID: PMC371275          DOI: 10.1172/JCI109584

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  DETERMINATION OF SERUM TRIGLYCERIDES.

Authors:  L A CARLSON
Journal:  J Atheroscler Res       Date:  1963 Jul-Aug

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Labelling of plasma proteins with radioactive iodine.

Authors:  A S MCFARLANE
Journal:  Biochem J       Date:  1956-01       Impact factor: 3.857

4.  Radioimmunological study of the surface protein of the human serum low-density lipoprotein: comparison of the native particle and the products obtained by tryptic treatment.

Authors:  S Goldstein; M J Chapman
Journal:  Biochem Biophys Res Commun       Date:  1979-03-15       Impact factor: 3.575

5.  Type III hyperlipoproteinemia: development of a VLDL ApoE gel isoelectric focusing technique and application in family studies.

Authors:  S W Weidman; B Suarez; J M Falko; J L Witztum; J Kolar; M Raben; G Schonfeld
Journal:  J Lab Clin Med       Date:  1979-04

6.  Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins.

Authors:  A L Catapano; S H Gianturco; P K Kinnunen; S Eisenberg; A M Gotto; L C Smith
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

Review 7.  The low-density lipoprotein pathway and its relation to atherosclerosis.

Authors:  J L Goldstein; M S Brown
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

8.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

9.  Role of microtubules in low density lipoprotein processing by cultured cells.

Authors:  R E Ostlund; B Pfleger; G Schonfeld
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

10.  Lipoprotein lipase from bovine milk. Isolation procedure, chemical characterization, and molecular weight analysis.

Authors:  P H Iverius; A M Ostlund-Lindqvist
Journal:  J Biol Chem       Date:  1976-12-25       Impact factor: 5.157

View more
  12 in total

1.  Effect of serum lipoproteins on the adenylate cyclase activity of rat liver plasma membranes.

Authors:  G Ghiselli; C R Sirtori; S Nicosia
Journal:  Biochem J       Date:  1981-06-15       Impact factor: 3.857

2.  Lipoprotein lipase secretion by human monocytes and rabbit alveolar macrophages in culture.

Authors:  E M Mahoney; J C Khoo; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

3.  Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins.

Authors:  E S Krul; M J Tikkanen; T G Cole; J M Davie; G Schonfeld
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Effect of fatty acids on lipid and apoprotein secretion and association in hepatocyte cultures.

Authors:  W Patsch; T Tamai; G Schonfeld
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

5.  Structure, immunology, and cell reactivity of low density lipoprotein from umbilical vein of a newborn type II homozygote.

Authors:  W Patsch; J L Witztum; R Ostlund; G Schonfeld
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

6.  Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy.

Authors:  Y Kleinman; S Eisenberg; Y Oschry; D Gavish; O Stein; Y Stein
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

7.  Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.

Authors:  R W Milne; P K Weech; L Blanchette; J Davignon; P Alaupovic; Y L Marcel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

8.  Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor.

Authors:  W März; M W Baumstark; H Scharnagl; V Ruzicka; S Buxbaum; J Herwig; T Pohl; A Russ; L Schaaf; A Berg
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein.

Authors:  E Sehayek; U Lewin-Velvert; T Chajek-Shaul; S Eisenberg
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

10.  Role of insulin in lipoprotein secretion by cultured rat hepatocytes.

Authors:  W Patsch; S Franz; G Schonfeld
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.